RO4929097

RO4929097
Identifiers
  • 2,2-Dimethyl-N-[(10S)-9-oxo-8-azatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-10-yl]-N-(2,2,3,3,3-pentafluoropropyl)propanediamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H20F5N3O3
Molar mass469.412 g·mol−1
3D model (JSmol)
  • O=C1Nc2ccccc2c2c(C1NC(=O)C(C(=O)NCC(C(F)(F)F)(F)F)(C)C)cccc2
  • InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1
  • Key:OJPLJFIFUQPSJR-INIZCTEOSA-N

RO4929097 (RG-4733) is a gamma secretase inhibitor being studied as an anti-cancer drug.[1] Targeting gamma secretase inhibits NOTCH signaling, which is upregulated in many forms of cancer.[2] The drug was initially developed by Roche for the treatment of Alzheimer's disease, but current research focuses on cancer.[3] Production was halted in 2010, but began again in 2014.[4]

Research

Over 35 phase I and II clinical trials have been performed, but no phase III trials have yet commenced.[5] Phase II studies have investigated the use of RO4929097 in ovarian cancer,[6] renal cell carcinoma in patients that were unsuccessful on anti-VEGF treatments,[7] metastatic pancreatic cancer,[8] advanced brain tumors,[9] and relapsed non-small cell lung cancer.[10]

Other planned clinical trials were terminated, because the drug became unavailable.[11]

References

  1. ^ Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF (October 2009). "Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties". Cancer Research. 69 (19): 7672–80. doi:10.1158/0008-5472.CAN-09-1843. PMC 5260798. PMID 19773430.
  2. ^ "Gamma-secretase/Notch signalling pathway inhibitor RO4929097". NCI Drug Dictionary. National Cancer Institute.
  3. ^ "RO4929097". IUPHAR/BPS Guide to PHARMACOLOGY.
  4. ^ "RG 4733". AdisInsight. Springer Nature Switzerland AG.
  5. ^ "Search for: RO4929097 - List Results - ClinicalTrials.gov".
  6. ^ Clinical trial number NCT01175343 for "RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer" at ClinicalTrials.gov
  7. ^ Clinical trial number NCT01141569 for "A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy" at ClinicalTrials.gov
  8. ^ Clinical trial number NCT01232829 for "Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer" at ClinicalTrials.gov
  9. ^ Clinical trial number NCT01122901 for "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma" at ClinicalTrials.gov
  10. ^ Clinical trial number NCT01070927 for "An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer" at ClinicalTrials.gov
  11. ^ Clinical trial number NCT01216787 for "RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery" at ClinicalTrials.gov

Strategi Solo vs Squad di Free Fire: Cara Menang Mudah!